{"id":29125,"date":"2026-02-07T19:22:44","date_gmt":"2026-02-07T19:22:44","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/longevity-market-mordor\/"},"modified":"2026-09-11T05:42:49","modified_gmt":"2026-09-10T20:42:49","slug":"longevity-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/longevity-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc7a5\uc218 \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/longevity-market-1767784860339-major-players.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/longevity-market-size-image-1767784278142.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 65\uc138 \uc774\uc0c1 \uc778\uad6c\uc758 \uae09\uc99d<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc5f0\ub839 \uad00\ub828 \ub9cc\uc131 \uc9c8\ud658\uc758 \uc99d\uac00\ud558\ub294 \ubd80\ub2f4<\/li>\n<li class=\"toc-level-3\">4.2.3 \ud68c\ucd98 \uc0dd\uba85\uacf5\ud559 \ubd84\uc57c\uc758 \ubca4\ucc98 \uce90\ud53c\ud0c8 &amp; SPAC \uae09\uc99d<\/li>\n<li class=\"toc-level-3\">4.2.4 CRISPR \ubc0f \uc720\uc804\uc790 \ud3b8\uc9d1 \ud50c\ub7ab\ud3fc\uc758 \ud601\uc2e0<\/li>\n<li class=\"toc-level-3\">4.2.5 AI \uae30\ubc18\uc758 \ucef4\ud4e8\ud130 \uc2dc\ubbac\ub808\uc774\uc158\uc744 \ud1b5\ud55c \ub178\ud654 \uce58\ub8cc\uc81c \ubc1c\uacac<\/li>\n<li class=\"toc-level-3\">4.2.6 \uc608\ubc29\uc801 \ub178\ud654 \uad00\ub9ac \ubd84\uc57c\uc5d0 \ub300\ud55c \uc9c0\ubd88\uc790\uc758 \uad00\uc2ec \ud655\ub300<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 \ub178\ud654\ub97c \uc9c8\ubcd1\uc73c\ub85c \ubd84\ub958\ud558\ub294 \uac83\uc5d0 \ub300\ud55c \uaddc\uc81c \ubd88\ud655\uc2e4\uc131<\/li>\n<li class=\"toc-level-3\">4.3.2 \ub178\ud654 \ubc29\uc9c0\uc81c\uc5d0 \ub300\ud55c \ub192\uc740 \uc784\uc0c1 \uc2dc\ud5d8 \ube44\uc6a9 \ubc0f \uae34 \uc18c\uc694 \uc2dc\uac04<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc7a5\uc218 \uc811\uadfc \ubd88\ud3c9\ub4f1\uc5d0 \ub300\ud55c \uc0dd\uba85\uc724\ub9ac\uc801 \uc6b0\ub824<\/li>\n<li class=\"toc-level-3\">4.3.4 \uc7a5\uc218 \uc81c\ud488\uc5d0 \ub300\ud55c \ub300\uc911\uc758 \ud68c\uc758\ub860 \ubc0f \u201c\uac00\uc9dc \uc57d\u201d \uc778\uc2dd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uac00\uce58 \/ \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778 \ubd84\uc11d\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.2 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uacf5\uae09\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (USD \uac00\uce58)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc\ubc95\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 \ub178\ud654\uc138\ud3ec\uc81c\uac70 \uc18c\ubd84\uc790<\/li>\n<li class=\"toc-level-3\">5.1.2 \ub178\ud654\uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-3\">5.1.3 \uc720\uc804\uc790 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.4 \uc138\ud3ec \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.5 \uc904\uae30\uc138\ud3ec &amp; \uc7ac\uc0dd \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.6 \uba74\uc5ed \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.7 \ub9c8\uc774\ud06c\ub85c\ubc14\uc774\uc634 \uc870\uc791<\/li>\n<li class=\"toc-level-3\">5.1.8 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uc804\ub2ec \ud50c\ub7ab\ud3fc\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \uc0dd\uccb4 \ub0b4 \uce58\ub8cc\uc81c<\/li>\n<li class=\"toc-level-3\">5.2.2 \uc0dd\uccb4 \uc678 \/ \uc138\ud3ec \uae30\ubc18 \ud50c\ub7ab\ud3fc<\/li>\n<li class=\"toc-level-3\">5.2.3 \ub514\uc9c0\ud138 \uc7a5\uc218 \uac1c\uc785<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc801\uc6a9 \ubd84\uc57c\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \uc2ec\ud608\uad00 \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.3.2 \uc2e0\uacbd\ud1f4\ud589\uc131 \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.3.3 \ub300\uc0ac \uc9c8\ud658 (\ub2f9\ub1e8\ubcd1, \ube44\ub9cc)<\/li>\n<li class=\"toc-level-3\">5.3.4 \uc885\uc591\ud559\uc801 \uc801\uc751\uc99d<\/li>\n<li class=\"toc-level-3\">5.3.5 \uadfc\uace8\uaca9\uacc4 &amp; \ub178\uc1e0<\/li>\n<li class=\"toc-level-3\">5.3.6 \ud53c\ubd80\uacfc &amp; \ubbf8\uc6a9<\/li>\n<li class=\"toc-level-3\">5.3.7 \uc548\uacfc<\/li>\n<li class=\"toc-level-3\">5.3.8 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \uc81c\uc57d &amp; \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5<\/li>\n<li class=\"toc-level-3\">5.4.2 \ud559\uc220 &amp; \uc5f0\uad6c \uae30\uad00<\/li>\n<li class=\"toc-level-3\">5.4.3 CRO &amp; CDMO<\/li>\n<li class=\"toc-level-3\">5.4.4 \uc6f0\ub2c8\uc2a4 \ud074\ub9ac\ub2c9 &amp; \uc7a5\uc218 \uc2a4\ud30c<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.5.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.5.1.3 \uba55\uc2dc\ucf54<\/li>\n<li class=\"toc-level-3\">5.5.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.5.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.5.2.2 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.5.2.3 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.5.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.5.2.6 \uc720\ub7fd \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.5.3 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.5.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.5.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.5.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.5.3.6 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.5.4 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.5.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.5.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.5.4.3 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74 \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.5.5 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.5.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.5.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.5.5.3 \ub0a8\ubbf8 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4(\uac00\ub2a5\ud55c \uacbd\uc6b0), \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 AbbVie Inc.<\/li>\n<li class=\"toc-level-3\">6.3.2 AgeX Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.3 Altos Labs<\/li>\n<li class=\"toc-level-3\">6.3.4 BioAge Labs<\/li>\n<li class=\"toc-level-3\">6.3.5 Bristol-Myers Squibb<\/li>\n<li class=\"toc-level-3\">6.3.6 Calico Life Sciences<\/li>\n<li class=\"toc-level-3\">6.3.7 Cambrian BioPharma<\/li>\n<li class=\"toc-level-3\">6.3.8 Clover Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.9 CohBar Inc.<\/li>\n<li class=\"toc-level-3\">6.3.10 Eli Lilly and Company<\/li>\n<li class=\"toc-level-3\">6.3.11 FoxBio<\/li>\n<li class=\"toc-level-3\">6.3.12 GlaxoSmithKline plc<\/li>\n<li class=\"toc-level-3\">6.3.13 Insilico Medicine<\/li>\n<li class=\"toc-level-3\">6.3.14 Juvenescence Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.15 Life Biosciences<\/li>\n<li class=\"toc-level-3\">6.3.16 Merck &amp; Co., Inc.<\/li>\n<li class=\"toc-level-3\">6.3.17 Ois\u00edn Biotechnologies<\/li>\n<li class=\"toc-level-3\">6.3.18 Pfizer Inc.<\/li>\n<li class=\"toc-level-3\">6.3.19 Rejuvenate Bio<\/li>\n<li class=\"toc-level-3\">6.3.20 Revel Pharmaceuticals<\/li>\n<li class=\"toc-level-3\">6.3.21 Serina Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.22 TheraSyn<\/li>\n<li class=\"toc-level-3\">6.3.23 Turn.Bio<\/li>\n<li class=\"toc-level-3\">6.3.24 Unity Biotechnology<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\uc7a5\uc218(Longevity) \uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc131\uc7a5 \uc804\ub9dd (2026-2031)<\/p>\n<p>1. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc804\ub9dd<\/p>\n<p>\uc7a5\uc218 \uc2dc\uc7a5\uc740 2026\ub144 316\uc5b5 3\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc5d0\uc11c 2031\ub144 468\uc5b5 6\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc608\uce21 \uae30\uac04(2026-2031) \ub3d9\uc548 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 8.18%\ub97c \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \ub178\ud654\ub97c \ub418\ub3cc\ub9b4 \uc218 \uc5c6\ub294 \uc2dc\uac04\uc758 \ud750\ub984\uc774 \uc544\ub2cc, \uc870\uc808 \uac00\ub2a5\ud55c \uc0dd\ubb3c\ud559\uc801 \uacbd\ub85c\ub85c \uc778\uc2dd\ud558\ub294 \uc57d\ubb3c \ubc1c\uacac\uc758 \uc804\ub7b5\uc801 \uc804\ud658\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \ub2e8\uc77c \uc138\ud3ec \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \ub77c\uc6b4\ub4dc\uc5d0 30\uc5b5 \ub2ec\ub7ec \uc774\uc0c1 \ud22c\uc790\ub418\ub294 \ubca4\ucc98 \uc790\uae08, CRISPR \uae30\ubc18 \uc720\uc804\uc790 \ud3b8\uc9d1\uc758 \uae09\uc18d\ud55c \ubc1c\uc804, \uc0dd\ubb3c\ud559\uc801 \uc5f0\ub839\uacfc \uc5f0\uacc4\ub41c \uac1c\uc785\uc744 \ubcf4\uc0c1\ud558\ub294 \ubcf4\ud5d8\uc0ac \uc2dc\ubc94 \uc0ac\uc5c5 \ub4f1\uc740 \ud655\uc7a5 \uac00\ub2a5\ud55c \ud68c\ucd98 \ud30c\uc774\ud504\ub77c\uc778\uc5d0 \ub300\ud55c \ud22c\uc790 \ud658\uacbd\uc774 \uc870\uc131\ub418\uc5c8\uc74c\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4. \uae30\uc874 \uc81c\uc57d\uc0ac\ub4e4\uc740 \ucd08\uae30 \ub2e8\uacc4 \ubc14\uc774\uc624\ud14d\uacfc\uc758 \uc704\ud5d8 \ubd84\uc0b0 \uc81c\ud734\ub97c \ud655\ub300\ud558\uace0 \uc788\uc73c\uba70, \ub514\uc9c0\ud138 \ubc14\uc774\uc624\ub9c8\ucee4\uc640 \ud6c4\uc131\uc720\uc804\ud559\uc801 \uc2dc\uacc4\ub294 \uc5f0\uad6c \ud1b5\ucc30\ub825\uc744 \uc18c\ube44\uc790 \uc218\uc900\uc758 \ud53c\ub4dc\ubc31 \ub8e8\ud504\ub85c \uc804\ud658\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc694\uc18c\ub4e4\uc774 \uacb0\ud569\ud558\uc5ec \uce58\ub8cc, \uc9c4\ub2e8, \uc0dd\ud65c \ubc29\uc2dd \uc591\uc2dd\uc774 \uc0c8\ub85c\uc6b4 \uc608\ubc29 \uce58\ub8cc \ubcf4\uc0c1 \uccb4\uacc4 \ub0b4\uc5d0\uc11c \uc218\ub834\ub428\uc5d0 \ub530\ub77c \uc7a5\uc218 \uc2dc\uc7a5\uc740 \uc9c0\uc18d\uc801\uc778 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc744 \uc704\ud55c \uae30\ubc18\uc744 \ub9c8\ub828\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>2. \uc8fc\uc694 \uc2dc\uc7a5 \uc138\ubd84\ud654 \ubd84\uc11d \uc694\uc57d<\/p>\n<p>*   \uce58\ub8cc\ubc95\ubcc4: 2025\ub144 \ub9e4\ucd9c\uc758 36.52%\ub97c \ucc28\uc9c0\ud558\uba70 \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud55c \uac83\uc740 \ub178\ud654 \uc138\ud3ec \uc81c\uac70 \uc18c\ubd84\uc790(Senolytic Small Molecules)\uc600\uc73c\uba70, \uc720\uc804\uc790 \uce58\ub8cc\ubc95\uc740 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 11.63%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc804\ub2ec \ud50c\ub7ab\ud3fc\ubcc4: 2025\ub144 \uc7a5\uc218 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 71.83%\ub97c \ucc28\uc9c0\ud55c \uac83\uc740 \uc0dd\uccb4 \ub0b4 \uce58\ub8cc\ubc95(In-Vivo Therapeutics)\uc774\uc5c8\uc73c\uba70, \ub514\uc9c0\ud138 \uc7a5\uc218 \uac1c\uc785(Digital Longevity Interventions)\uc740 2031\ub144\uae4c\uc9c0 12.78%\uc758 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc801\uc6a9 \ubd84\uc57c\ubcc4: 2025\ub144 \ub9e4\ucd9c\uc758 27.37%\ub294 \uc885\uc591\ud559\uc801 \uc801\uc751\uc99d(Oncological Indications)\uc774 \ucc28\uc9c0\ud588\uc73c\uba70, \uc2e0\uacbd\ud1f4\ud589\uc131 \uc9c8\ud658(Neurodegenerative Disorders)\uc740 2031\ub144\uae4c\uc9c0 10.52%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: 2025\ub144 \ub9e4\ucd9c\uc758 63.83%\ub294 \uc81c\uc57d \ubc0f \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5(Pharmaceutical &#038; Biotechnology Companies)\uc774 \ucc28\uc9c0\ud588\uc73c\uba70, \uc6f0\ub2c8\uc2a4 \ud074\ub9ac\ub2c9 \ubc0f \uc7a5\uc218 \uc2a4\ud30c(Wellness Clinics &#038; Longevity Spas)\ub294 2031\ub144\uae4c\uc9c0 11.22%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ub9e4\ucd9c\uc758 41.23%\ub294 \ubd81\ubbf8(North America)\uac00 \uae30\ub85d\ud588\uc73c\ub098, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591(Asia-Pacific) \uc9c0\uc5ed\uc740 \uc608\uce21 \uae30\uac04 \ub3d9\uc548 10.35%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>3. \uae00\ub85c\ubc8c \uc7a5\uc218 \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825 (\uc131\uc7a5 \ub3d9\ub825)<\/p>\n<p>*   65\uc138 \uc774\uc0c1 \uc778\uad6c\uc758 \uae09\uc99d: \uc720\uc5d4\uc740 2050\ub144\uae4c\uc9c0 65\uc138 \uc774\uc0c1 \uc778\uad6c\uac00 16\uc5b5 \uba85\uc5d0 \ub2ec\ud560 \uac83\uc73c\ub85c \uc608\uce21\ud558\uba70, \uc774\ub294 2021\ub144 7\uc5b5 6,100\ub9cc \uba85\uc758 \ub450 \ubc30 \uc774\uc0c1\uc785\ub2c8\ub2e4. 2024\ub144 \uc720\uc5d4 \uc5c5\ub370\uc774\ud2b8\uc5d0 \ub530\ub974\uba74, 2030\ub144\ub300 \uc911\ubc18\uc5d0\ub294 80\uc138 \uc774\uc0c1 \uc778\uad6c\uac00 2\uc5b5 6,500\ub9cc \uba85\uc5d0 \ub2ec\ud558\uace0, 2070\ub144\ub300 \ud6c4\ubc18\uc5d0\ub294 65\uc138 \uc774\uc0c1 \uc778\uad6c\uac00 \uc804 \uc138\uacc4\uc801\uc73c\ub85c 22\uc5b5 \uba85\uc73c\ub85c \uae09\uc99d\ud560 \uac83\uc785\ub2c8\ub2e4. \uc77c\ubcf8\uc740 2024\ub144 65\uc138 \uc774\uc0c1 \uc778\uad6c\uac00 29%\ub97c \ucc28\uc9c0\ud558\uba70, \ub178\uc778 \ubc29\ubb38 \uc9c4\ub8cc \uc2dc \uc7a5\uc218 \uc9c4\ub2e8\uc744 \ud45c\uc900\ud654\ud558\ub294 \uc2e4\ubc84 \uc778\uc801 \uc790\uc6d0 \uc13c\ud130\uc5d0 \uc790\uae08\uc744 \uc9c0\uc6d0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc911\uad6d\uc758 \uc81c14\ucc28 5\uac1c\ub144 \uacc4\ud68d\uc740 \ub178\uc778 \ub3cc\ubd04 \uc778\ud504\ub77c\uc5d0 3\uc870 2\ucc9c\uc5b5 \uc704\uc548\uc744 \ubc30\uc815\ud588\uc73c\uba70, \ubbf8\uad6d \uba54\ub514\ucf00\uc5b4\ub294 \ub9cc\uc131 \uc9c8\ud658 \uad00\ub9ac\uc5d0 \uc5f0\uac04 \uc218\ud61c\uc790\ub2f9 23,000\ub2ec\ub7ec\ub97c \uc9c0\ucd9c\ud558\uace0 \uc788\uc5b4, \ub178\ud654 \uc138\ud3ec \uc81c\uac70\ub97c \ud1b5\ud55c \uc9c8\ubcd1 \uc774\ud658\uc728 \uc555\ucd95\uc774 \ud3c9\uc0dd \uc9c0\ucd9c\uc744 \ud06c\uac8c \ub0ae\ucd9c \uc218 \uc788\uc74c\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4.<br \/>\n*   \uc5f0\ub839 \uad00\ub828 \ub9cc\uc131 \uc9c8\ud658 \ubd80\ub2f4 \uc99d\uac00: \uc2ec\ud608\uad00 \uc9c8\ud658, \uc554, \uc2e0\uacbd\ud1f4\ud589\uc131 \uc9c8\ud658, \ub300\uc0ac \uc99d\ud6c4\uad70\uc740 \uc804 \uc138\uacc4 \uc0ac\ub9dd \uc6d0\uc778\uc758 71%\ub97c \ucc28\uc9c0\ud569\ub2c8\ub2e4. \uc54c\uce20\ud558\uc774\uba38\ubcd1\ub9cc\uc73c\ub85c\ub3c4 2024\ub144 \ubbf8\uad6d\uc5d0\uc11c 3,450\uc5b5 \ub2ec\ub7ec\uc758 \uc758\ub8cc\ube44\uac00 \uc18c\uc694\ub418\uc5c8\uc73c\uba70, CMS\ub294 \ub808\uce74\ub124\ub9d9(lecanemab)\uc5d0 \ub300\ud574 \uc2dc\ud310 \ud6c4 \uc548\uc804\uc131 \uac10\uc2dc\uc640 \uc5f0\uacc4\ub41c \uc2e0\uc18d \uc2b9\uc778 \uacbd\ub85c\ub97c \ud1b5\ud574 \ubcf4\uc0c1\uc744 \uc2b9\uc778\ud588\uc2b5\ub2c8\ub2e4. \uc804\uc784\uc0c1 \uc5f0\uad6c\ub294 \ub2e4\uc0ac\ud2f0\ub2d9-\ud018\ub974\uc138\ud2f4(dasatinib-plus-quercetin)\uc774 \ud2b9\ubc1c\uc131 \ud3d0\uc12c\uc720\uc99d \ubc0f \uace8\uad00\uc808\uc5fc\uc5d0\uc11c \ub178\ud654 \uc138\ud3ec\ub97c \uc81c\uac70\ud568\uc744 \ubcf4\uc5ec\uc8fc\uc9c0\ub9cc, \uc778\uccb4 \uc870\uc9c1\uc5d0\uc11c \ub178\ud654 \ubd80\ub2f4\uc744 \uc815\ub7c9\ud654\ud558\ub294 \ubc14\uc774\uc624\ub9c8\ucee4 \uc5c6\uc774\ub294 \uc804\ud658\uc774 \ub290\ub824\uc9d1\ub2c8\ub2e4.<br \/>\n*   \ud68c\ucd98 \uc0dd\uba85\uacf5\ud559 \ubd84\uc57c \ubca4\ucc98 \uce90\ud53c\ud0c8 \ubc0f SPAC \uae09\uc99d: \uc54c\ud1a0\uc2a4 \ub7a9\uc2a4(Altos Labs)\ub294 \uc138\ud3ec \ud6c4\uc131\uc720\uc804\ud559\uc801 \uc5f0\ub839\uc744 \uc7ac\uc124\uc815\ud558\ub294 \ubd80\ubd84 \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \uc811\uadfc\ubc95\uc744 \ucd94\uad6c\ud558\uae30 \uc704\ud574 30\uc5b5 \ub2ec\ub7ec\uc758 \uc2dc\ub9ac\uc988 A \uc790\uae08\uc744 \uc720\uce58\ud588\uc2b5\ub2c8\ub2e4. \ub860\uc81c\ube44\ud2f0 \ubc14\uc774\uc624\uba54\ub514\uceec(Longevity Biomedical)\uc740 2,680\ub9cc \ub2ec\ub7ec\uc758 SPAC \ud569\ubcd1\uc744 \ud1b5\ud574 \uacf5\uacf5 \uc790\ubcf8\uc5d0 \uc811\uadfc\ud558\uc5ec \ub178\ud654 \uad00\ub828 \uc8fc\uc2dd \uc0c1\uc7a5\uc758 \uc120\ub840\ub97c \ub9cc\ub4e4\uc5c8\uc2b5\ub2c8\ub2e4. \ub808\ud2b8\ub85c \ubc14\uc774\uc624\uc0ac\uc774\uc5b8\uc2a4(Retro Biosciences)\ub294 \uc790\uac00\ud3ec\uc2dd \ubc0f \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \ud50c\ub7ab\ud3fc\uc5d0 10\uc5b5 \ub2ec\ub7ec\ub97c \ud22c\uc790\ud558\uc5ec 10\ub144 \uc218\uba85 \uc5f0\uc7a5 \ud504\ub85c\uc81d\ud2b8\uc5d0 \ub300\ud55c \ud22c\uc790\uc790\ub4e4\uc758 \uad00\uc2ec\uc744 \ubcf4\uc5ec\uc8fc\uc5c8\uc2b5\ub2c8\ub2e4.<br \/>\n*   CRISPR \ubc0f \uae30\ud0c0 \uc720\uc804\uc790 \ud3b8\uc9d1 \ub3c4\uad6c\uc758 \ud601\uc2e0: FDA\ub294 2023\ub144 12\uc6d4 \ud5e4\ubaa8\uae00\ub85c\ube48\ubcd1\uc5d0 \ub300\ud55c \uce74\uc2a4\uac8c\ube44(Casgevy)\ub97c \uc2b9\uc778\ud558\uc5ec \uc0dd\uccb4 \uc678 CRISPR \ud3b8\uc9d1\uc744 \uac80\uc99d\ud558\uace0 \uc0dd\uccb4 \ub0b4 \uc804\ub2ec \ud22c\uc790\uc5d0 \ubc15\ucc28\ub97c \uac00\ud588\uc2b5\ub2c8\ub2e4. \ubca0\uc774\uc2a4 \ubc0f \ud504\ub77c\uc784 \uc5d0\ub514\ud130\ub294 \uc774\uc911 \uac00\ub2e5 \ud30c\uc190 \uc5c6\uc774 \ub2e8\uc77c \uc5fc\uae30 \uc624\ub958\ub97c \uad50\uc815\ud558\uba70, \uc870\ub85c\uc99d \ubc0f \uac00\uc18d \ub178\ud654\ub97c \ubaa8\ubc29\ud558\ub294 \ud154\ub85c\ubbf8\uc5b4 \uae30\ub2a5 \uc7a5\uc560 \ubaa8\ub378\uc5d0\uc11c \uac00\ub2a5\uc131\uc744 \ubcf4\uc5ec\uc8fc\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc608\ubc29\uc801 \ub178\ud654 \uad00\ub9ac \ubd84\uc57c\uc5d0\uc11c \uc9c0\ubd88\uc790\uc758 \uad00\uc2ec \ud655\ub300: \ubcf4\ud5d8\uc0ac\ub4e4\uc740 \uc0dd\ubb3c\ud559\uc801 \uc5f0\ub839 \uac10\uc18c\uc5d0 \ub300\ud55c \ubcf4\uc0c1\uc744 \uc2dc\ubc94\uc801\uc73c\ub85c \uc2dc\ud589\ud558\uba70 \ub370\uc774\ud130 \uae30\ubc18 \ub3c4\uad6c\uc758 \uc0c1\uc5c5\uc801 \ub17c\ub9ac\ub97c \ub4b7\ubc1b\uce68\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>4. \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778<\/p>\n<p>*   \ub178\ud654\ub97c \uc9c8\ubcd1\uc73c\ub85c \ubd84\ub958\ud558\ub294 \uaddc\uc81c \ubd88\ud655\uc2e4\uc131: FDA\ub294 \ub178\ud654\ub97c \uc9c4\ub2e8 \uac00\ub2a5\ud55c \uc801\uc751\uc99d\uc774 \uc544\ub2cc \uc704\ud5d8 \uc694\uc18c\ub85c \ucde8\uae09\ud558\uc5ec, \uc2a4\ud3f0\uc11c\ub4e4\uc774 \ud5c8\uc57d \ub610\ub294 \ub300\uc0ac \uc99d\ud6c4\uad70\uacfc \uac19\uc740 \ub300\ub9ac \uc885\uc810(proxy endpoints)\uc73c\ub85c \uc804\ud658\ud558\ub3c4\ub85d \uac15\uc694\ud569\ub2c8\ub2e4. \uba54\ud2b8\ud3ec\ub974\ubbfc\uc744 \ub178\ud654 \uc9c0\uc5f0 \uce58\ub8cc\uc81c\ub85c \ubd84\ub958\ud558\uae30 \uc704\ud55c TAME \uc5f0\uad6c\ub294 2026\ub144\uae4c\uc9c0 \uc9c4\ud589 \uc911\uc785\ub2c8\ub2e4. EMA\uc758 2024\ub144 \ucd08\uc548 \uc9c0\uce68\uc740 \uc5ec\ub7ec \uc7a5\uae30 \uc2dc\uc2a4\ud15c\uc5d0 \uac78\uce5c \uae30\ub2a5\uc801 \uc774\ub4dd\uc774 \uc2b9\uc778 \uae30\uc900\uc744 \ucda9\uc871\ud560 \uc218 \uc788\uc74c\uc744 \uc2dc\uc0ac\ud588\uc9c0\ub9cc, \uac80\uc99d\ub41c \ub300\uccb4 \ubc14\uc774\uc624\ub9c8\ucee4\uc758 \ubd80\uc871\uc774 \ucc44\ud0dd\uc744 \ub2a6\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub192\uc740 \uc784\uc0c1 \uc2dc\ud5d8 \ube44\uc6a9 \ubc0f \ub2e4\ub144\uac04\uc758 \uae30\uac04: 2\uc0c1 \ub178\ud654 \uc2dc\ud5d8\uc740 700\ub9cc~2,000\ub9cc \ub2ec\ub7ec\uac00 \uc18c\uc694\ub418\uba70, 3\uc0c1 \uc5f0\uad6c\ub294 \uc9c8\ubcd1 \ubc1c\uc0dd\ub960 \ub610\ub294 \uc0ac\ub9dd\ub960\uc5d0 \ub300\ud55c \uc7a5\uae30 \ucd94\uc801 \uad00\ucc30\uc774 \ud544\uc694\ud558\ubbc0\ub85c 1\uc5b5 \ub2ec\ub7ec\ub97c \ucd08\uacfc\ud558\ub294 \uacbd\uc6b0\uac00 \ub9ce\uc2b5\ub2c8\ub2e4. FDA\uac00 \uc2b9\uc778\ud55c \ubc14\uc774\uc624\ub9c8\ucee4\uac00 \uc5c6\uc73c\uba74 \uc2a4\ud3f0\uc11c\ub4e4\uc740 \ub300\uaddc\ubaa8 \uc0d8\ud50c \ud06c\uae30\ub97c \uc720\ub3c4\ud558\ub294 \ub178\ub3d9 \uc9d1\uc57d\uc801\uc778 \uae30\ub2a5\uc801 \uc885\uc810\uc5d0 \uc758\uc874\ud569\ub2c8\ub2e4.<br \/>\n*   \uc7a5\uc218 \uc811\uadfc \ubd88\ud3c9\ub4f1\uc5d0 \ub300\ud55c \uc0dd\uba85\uc724\ub9ac\uc801 \uc6b0\ub824: \uc7a5\uc218 \uce58\ub8cc\ubc95\uc758 \uc811\uadfc\uc131 \ubd88\ud3c9\ub4f1\uc5d0 \ub300\ud55c \uc724\ub9ac\uc801 \ub17c\uc758\uac00 \uc9c0\uc18d\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub178\ud654 \ubc29\uc9c0 \uc81c\ud488\uc5d0 \ub300\ud55c \ub300\uc911\uc758 \ud68c\uc758\ub860 \ubc0f &#8220;\uac00\uc9dc \uc57d&#8221; \uc778\uc2dd: \ub300\uc911\uc758 \ubd88\uc2e0\uacfc \uc798\ubabb\ub41c \uc815\ubcf4\uac00 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>5. \uc138\ubd80 \uc2dc\uc7a5 \uc138\ubd84\ud654 \ubd84\uc11d<\/p>\n<p>*   \uce58\ub8cc\ubc95\ubcc4: \uc720\uc804\uc790 \uce58\ub8cc\ubc95\uc740 \ub9cc\uc131 \ud1f4\ud589\uc131 \uc9c8\ud658\uc5d0\uc11c \ubc18\ubcf5 \ud22c\uc5ec\ub97c \uac00\ub2a5\ud558\uac8c \ud558\ub294 \uc544\ub370\ub178 \uad00\ub828 \ubc14\uc774\ub7ec\uc2a4(AAV) \uac1c\uc120\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 11.63%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc785\ub2c8\ub2e4. \ub178\ud654 \uc138\ud3ec \uc81c\uac70 \uc18c\ubd84\uc790\ub294 2025\ub144 \ub9e4\ucd9c\uc758 36.52%\ub97c \ucc28\uc9c0\ud558\uba70 \uc7a5\uc218 \uc2dc\uc7a5\uc5d0\uc11c \uac00\uc7a5 \ud070 \uae30\uc5ec\uc790\ub85c \uc790\ub9ac\ub9e4\uae40\ud588\uc2b5\ub2c8\ub2e4. 1\uc138\ub300 \uc57d\ubb3c\uc740 \ube44\ud45c\uc801 \ub3c5\uc131 \ubb38\uc81c\uc5d0 \uc9c1\uba74\ud558\uc5ec \uc138\ud3ec \uc0ac\uba78\uc744 \uc720\ubc1c\ud558\uc9c0 \uc54a\uace0 SASP(Senescence-Associated Secretory Phenotype) \ubc30\ucd9c\uc744 \uc81c\ud55c\ud558\ub294 \ub178\ud654 \uc870\uc808 \ud654\ud569\ubb3c(senomorphic compounds)\ub85c\uc758 \uc804\ud658\uc744 \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc804\ub2ec \ud50c\ub7ab\ud3fc\ubcc4: \uc0dd\uccb4 \ub0b4 \uce58\ub8cc\ubc95\uc740 \uc18c\ubd84\uc790 \ubc0f \uc804\uc2e0 \ud22c\uc5ec \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\uc5d0 \ud798\uc785\uc5b4 2025\ub144 \ub9e4\ucd9c\uc758 71.83%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \ud6c4\uc131\uc720\uc804\ud559\uc801 \uc2dc\uacc4 \ubc0f \uc6e8\uc5b4\ub7ec\ube14 \ubc14\uc774\uc624\ub9c8\ucee4 \ud50c\ub7ab\ud3fc\uc744 \ud3ec\ud568\ud558\ub294 \ub514\uc9c0\ud138 \uc7a5\uc218 \uac1c\uc785\uc740 \uc5f0\uac04 12.78%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc801\uc6a9 \ubd84\uc57c\ubcc4: \uc885\uc591\ud559\uc801 \uc801\uc751\uc99d\uc740 \ud56d\uc885\uc591 \ub178\ud654 \uc138\ud3ec \uc81c\uac70 \uc801\uc6a9 \ubc0f \ud654\ud559 \uc694\ubc95 \uc720\ubc1c \ub178\ud654\ub97c \uc644\ud654\ud558\ub294 \uc804\ub7b5\uc744 \ubc18\uc601\ud558\uc5ec 2025\ub144 \ub9e4\ucd9c\uc758 27.37%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \ub808\uce74\ub124\ub9d9 \ubc0f \ub3c4\ub098\ub124\ub9d9(donanemab)\uc758 FDA \uc2b9\uc778\uc740 \uc9c8\ubcd1 \uc870\uc808 \uc811\uadfc\ubc95\uc744 \uac80\uc99d\ud558\uace0 \uc2e0\uacbd\ud1f4\ud589\uc131 \uc9c8\ud658\uc744 10.52%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \ubd84\uc57c\ub85c \ub04c\uc5b4\uc62c\ub838\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: \uc81c\uc57d \ubc0f \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5\uc740 \ub0b4\ubd80 \ud30c\uc774\ud504\ub77c\uc778 \ubc0f \uc804\ub7b5\uc801 \uc81c\ud734\ub97c \ud1b5\ud574 2025\ub144 \ub9e4\ucd9c\uc758 63.83%\ub97c \ucc3d\ucd9c\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc6f0\ub2c8\uc2a4 \ud074\ub9ac\ub2c9 \ubc0f \uc7a5\uc218 \uc2a4\ud30c\ub294 \ubd80\uc720\ud55c \uc18c\ube44\uc790\ub4e4\uc774 \ub178\ud654 \uc138\ud3ec \uc81c\uac70\uc81c, \uc904\uae30\uc138\ud3ec \uc8fc\uc785 \ubc0f \uc9c0\uc18d\uc801\uc778 \ubaa8\ub2c8\ud130\ub9c1\uc744 \ud1b5\ud569\ud55c \ud504\ub85c\ud1a0\ucf5c\uc744 \uc694\uad6c\ud568\uc5d0 \ub530\ub77c \uc5f0\uac04 11.22% \uc131\uc7a5\ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p>6. \uc9c0\uc5ed\ubcc4 \ubd84\uc11d<\/p>\n<p>*   \ubd81\ubbf8: NIH\uc758 37\uc5b5 \ub2ec\ub7ec \ub178\ud654 \uc5f0\uad6c \ud560\ub2f9 \ubc0f \uc2e4\ub9ac\ucf58 \ubc38\ub9ac\uc758 \uafb8\uc900\ud55c \ubca4\ucc98 \uc790\uae08 \uc9c0\uc6d0\uc5d0 \ud798\uc785\uc5b4 2025\ub144 \ub9e4\ucd9c\uc758 41.23%\ub97c \ucc3d\ucd9c\ud588\uc2b5\ub2c8\ub2e4. \ubbf8\uad6d\uc740 120\uac1c \uc774\uc0c1\uc758 \uc7a5\uc218 \uad00\ub828 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc9c4\ud589\ud558\uace0 \uc788\uc9c0\ub9cc, \uaddc\uc81c \ubd88\ud655\uc2e4\uc131\uc774 \uc2dc\uc7a5 \ucd9c\uc2dc \uc18d\ub3c4\ub97c \ub2a6\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: 2031\ub144\uae4c\uc9c0 10.35%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc77c\ubcf8\uc740 \ubcf4\ud3b8\uc801 \uc758\ub8cc \ubcf4\uc7a5 \ub0b4\uc5d0 \uc7a5\uc218 \uc9c4\ub2e8\uc744 \ud1b5\ud569\ud558\uace0, \uc911\uad6d\uc740 \uc608\ubc29 \uc778\ud504\ub77c\uc5d0 16\uc870 \uc704\uc548\uc744 \ud22c\uc790\ud558\uba70, \uc778\ub3c4\ub294 \uc120\uc9c4 \uce58\ub8cc\ubc95\uc5d0 \ub300\ud55c \uc811\uadfc\uc131\uc774 \uace0\ub974\uc9c0 \uc54a\uc74c\uc5d0\ub3c4 \ubd88\uad6c\ud558\uace0 \ub178\uc778 \ub3cc\ubd04 \ud504\ub85c\uadf8\ub7a8\uc744 \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud55c\uad6d\uacfc \ud638\uc8fc\ub294 \ub178\ud654 \uce58\ub8cc \uacbd\ub85c\ub97c \uba85\ud655\ud788 \ud558\ub294 \uc9c0\uce68\uc744 \ud655\uc815\ud558\uc5ec \ub354 \ube60\ub978 \uc2b9\uc778\uc744 \uc6d0\ud558\ub294 \ubc14\uc774\uc624\ud14d\uc744 \uc720\uce58\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: EMA\uc758 \ub2e4\uc911 \uc2dc\uc2a4\ud15c \uc885\uc810\uc5d0 \ub300\ud55c \ud5c8\uc6a9\uc801\uc778 \uc785\uc7a5\uc774 \uc2b9\uc778\uc744 \uac00\uc18d\ud654\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \uc2a4\uc704\uc2a4\uc758 \ud504\ub9ac\ubbf8\uc5c4 \ud074\ub9ac\ub2c9 \ubc00\uc9d1 \uc9c0\uc5ed\uc740 \uc804 \uc138\uacc4 \uace0\uac1d\uc744 \uc720\uce58\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74: UAE\ub294 \ub3d9\uc815\uc801 \uc0ac\uc6a9 \uaddc\uce59\uc5d0 \ub530\ub77c \uc904\uae30\uc138\ud3ec \ud074\ub9ac\ub2c9\uc5d0 \uba74\ud5c8\ub97c \ubd80\uc5ec\ud558\uace0, \ub0a8\uc544\ud504\ub9ac\uce74 \uacf5\ud654\uad6d\uc740 \ud5c8\uc57d\uc5d0 \ub300\ud55c MSC \uce58\ub8cc\ubc95\uc744 \uc2b9\uc778\ud558\ub294 \ub4f1 \uc2e0\ud765 \uc2dc\uc7a5\uc73c\ub85c \ub0a8\uc544 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>7. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>50\uac1c \uc774\uc0c1\uc758 \uc784\uc0c1 \ub2e8\uacc4 \uae30\uc5c5\uc774 \ud65c\ub3d9\ud558\uace0 \uc788\uc73c\uba70, \uc5b4\ub5a4 \uae30\uc5c5\ub3c4 5% \uc774\uc0c1\uc758 \uc810\uc720\uc728\uc744 \ucc28\uc9c0\ud558\uc9c0 \uc54a\uc544 \ud1b5\ud569\uc5d0 \uc801\ud569\ud55c \uace0\ub3c4\ub85c \ubd84\uc0b0\ub41c \ud658\uacbd\uc744 \ud615\uc131\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc560\ube0c\ube44(AbbVie)\uc758 \uce7c\ub9ac\ucf54(Calico)\uc640\uc758 15\uc5b5 \ub2ec\ub7ec \uc5f0\uc7a5\uc740 \ub300\ud615 \uc81c\uc57d\uc0ac\ub4e4\uc758 \ub178\ud654 \ud50c\ub7ab\ud3fc\uc5d0 \ub300\ud55c \uad00\uc2ec\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uc54c\ud1a0\uc2a4 \ub7a9\uc2a4\ub294 30\uc5b5 \ub2ec\ub7ec\uc758 \uc790\uae08\uc744 \ud65c\uc6a9\ud558\uc5ec \ub2e8\uae30\uc801\uc778 \uc218\uc775 \uc555\ub825 \uc5c6\uc774 \uc138\ud3ec \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \ud601\uc2e0\uc744 \ucd94\uad6c\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc778\uc2e4\ub9ac\ucf54 \uba54\ub514\uc2a8(Insilico Medicine) \ubc0f \uc778\ud2f0\uadf8\ub808\uc774\ud2f0\ub4dc \ubc14\uc774\uc624\uc0ac\uc774\uc5b8\uc2a4(Integrated Biosciences)\uc640 \uac19\uc740 AI \uae30\ubc18 \uacbd\uc7c1\uc790\ub4e4\uc740 \ubc1c\uacac\uc744 \uac00\uc18d\ud654\ud558\uace0 IND(\uc784\uc0c1\uc2dc\ud5d8\uacc4\ud68d) \uc2e0\uccad \uc2dc\uac04\uc744 \ub2e8\ucd95\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \ub178\ud654 \uc138\ud3ec \uc81c\uac70\uc81c\uc5d0 \ub300\ud55c \ud2b9\ud5c8 \ubc1c\ud589\uc740 2022\ub144\uc5d0\uc11c 2024\ub144 \uc0ac\uc774\uc5d0 40% \uc99d\uac00\ud558\uc5ec, IP \ud3ec\ud2b8\ud3f4\ub9ac\uc624\uac00 \ubbf8\ub798 \ub77c\uc774\uc120\uc2f1 \ubc0f M&#038;A \ud65c\ub3d9\uc744 \uc8fc\ub3c4\ud560 \uac83\uc784\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4.<\/p>\n<p>8. \uc8fc\uc694 \uc0b0\uc5c5 \ub9ac\ub354<\/p>\n<p>\ube0c\ub9ac\uc2a4\ud1a8-\ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045(Bristol-Myers Squibb), \uc560\ube0c\ube44(AbbVie), \uc77c\ub77c\uc774 \ub9b4\ub9ac \uc564 \ucef4\ud37c\ub2c8(Eli Lilly and Company), \uce7c\ub9ac\ucf54 \ub77c\uc774\ud504 \uc0ac\uc774\uc5b8\uc2a4(Calico Life Sciences), \uc720\ub2c8\ud2f0 \ubc14\uc774\uc624\ud14c\ud06c\ub180\ub85c\uc9c0(Unity Biotechnology) \ub4f1\uc774 \uc8fc\uc694 \ud50c\ub808\uc774\uc5b4\ub85c \ud65c\ub3d9\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>9. \ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2025\ub144 12\uc6d4: \uc2dc\ud50c\ub77c(Cipla)\ub294 DCGI \uc2b9\uc778 \ud6c4 2~3\ub4f1\uae09 \ubb34\ub98e \uace8\uad00\uc808\uc5fc\uc5d0 \ub300\ud55c \ub3d9\uc885 MSC \uce58\ub8cc\uc81c\uc778 \uc2dc\ud50c\ub85c\uc2a4\ud15c(Ciplostem)\uc744 \ucd9c\uc2dc\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 12\uc6d4: FDA\ub294 \uc704\uc2a4\ucf67-\uc62c\ub4dc\ub9ac\uce58 \uc99d\ud6c4\uad70\uc5d0 \ub300\ud55c \ucd5c\ucd08\uc758 \uc138\ud3ec \uae30\ubc18 \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc778 \uc640\uc2a4\ud0a4\ub77c(Waskyra)\ub97c \uc2b9\uc778\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 11\uc6d4: \ub178\ubc14\ud2f0\uc2a4(Novartis)\ub294 \uc131\uc778\uc5d0\uac8c SMA \uc720\uc804\uc790 \ub300\uccb4 \uce58\ub8cc\ubc95\uc744 \ud655\uc7a5\ud558\ub294 \uc774\ud2b8\ube44\uc2a4\ub9c8(Itvisma)\uc5d0 \ub300\ud574 FDA \uc2b9\uc778\uc744 \ubc1b\uc558\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 8\uc6d4: \uc624\ud478\uc2a4 \uc81c\ub124\ud2f1\uc2a4(Opus Genetics)\ub294 \ubca0\uc2a4\ud2b8\ubcd1(Best disease)\uc5d0 \ub300\ud55c \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc758 1\/2\uc0c1 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc2dc\uc791\ud558\uae30 \uc704\ud55c FDA \uc2b9\uc778\uc744 \ud68d\ub4dd\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc0b6\uc758 \uc9c8\uc744 \ub192\uc774\uace0 \ub178\ud654\uc640 \uad00\ub828\ub41c \ub9cc\uc131 \uc9c8\ud658\uc744 \uc608\ubc29\ud558\ub294 &#8216;\uc7a5\uc218(Longevity)&#8217; \uc2dc\uc7a5\uc5d0 \ub300\ud55c \uc2ec\uce35 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \ubcf4\uace0\uc11c\uc5d0 \ub530\ub974\uba74, \uae00\ub85c\ubc8c \uc7a5\uc218 \uc2dc\uc7a5\uc740 2031\ub144\uae4c\uc9c0 468\uc5b5 6\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc5d0 \ub3c4\ub2ec\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, 2026\ub144\ubd80\ud130 \uc5f0\ud3c9\uade0 8.18%\uc758 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uc804\ub9dd\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5\uc758 \uc8fc\uc694 \ub3d9\ub825\uc73c\ub85c\ub294 65\uc138 \uc774\uc0c1 \uc778\uad6c\uc758 \uae09\uc99d, \ub178\ud654 \uad00\ub828 \ub9cc\uc131 \uc9c8\ud658 \ubd80\ub2f4 \uc99d\uac00, \ud68c\ucd98 \uc0dd\uba85\uacf5\ud559 \ubd84\uc57c\uc758 \ubca4\ucc98 \uce90\ud53c\ud0c8 \ubc0f SPAC \ud22c\uc790 \uae09\uc99d, CRISPR \ubc0f \uc720\uc804\uc790 \ud3b8\uc9d1 \ud50c\ub7ab\ud3fc\uc758 \ud601\uc2e0\uc801\uc778 \ubc1c\uc804, AI \uae30\ubc18 \ub178\ud654 \uc138\ud3ec \uce58\ub8cc\uc81c(Seno Therapeutics) \ubc1c\uacac, \uadf8\ub9ac\uace0 \uc608\ubc29\uc801 \ub178\ud654 \uad00\ub9ac(Preventive Aging Care)\uc5d0 \ub300\ud55c \ubcf4\ud5d8\uc0ac\uc758 \uad00\uc2ec \ud655\ub300 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \ub178\ud654\ub97c \uc9c8\ubcd1\uc73c\ub85c \ubd84\ub958\ud558\ub294 \ub370 \ub300\ud55c \uaddc\uc81c \ubd88\ud655\uc2e4\uc131, \ub178\ud654 \ubc29\uc9c0\uc81c(Geroprotectors)\uc758 \ub192\uc740 \uc784\uc0c1 \uc2dc\ud5d8 \ube44\uc6a9 \ubc0f \uae34 \uac1c\ubc1c \uae30\uac04, \uc7a5\uc218 \uae30\uc220 \uc811\uadfc \ubd88\uade0\ud615\uc5d0 \ub300\ud55c \uc0dd\uba85 \uc724\ub9ac\uc801 \uc6b0\ub824, \uadf8\ub9ac\uace0 \uc7a5\uc218 \uc81c\ud488\uc5d0 \ub300\ud55c \ub300\uc911\uc758 \ud68c\uc758\uc801\uc778 \uc2dc\uac01\uacfc &#8216;\uac00\uc9dc \uc57d&#8217; \uc778\uc2dd \ub4f1\uc774 \uc9c0\uc801\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5\uc740 \uce58\ub8cc\ubc95, \uc804\ub2ec \ud50c\ub7ab\ud3fc, \uc801\uc6a9 \ubd84\uc57c, \ucd5c\uc885 \uc0ac\uc6a9\uc790, \uadf8\ub9ac\uace0 \uc9c0\uc5ed\ubcc4\ub85c \uc138\ubd84\ud654\ub418\uc5b4 \ubd84\uc11d\ub429\ub2c8\ub2e4.<br \/>\n\uce58\ub8cc\ubc95\ubcc4\ub85c\ub294 \ub178\ud654 \uc138\ud3ec \uc81c\uac70 \uc18c\ubd84\uc790(Senolytic Small Molecules), \ub178\ud654 \uc138\ud3ec \uc870\uc808\uc81c(Senomorphic Agents), \uc720\uc804\uc790 \uce58\ub8cc, \uc138\ud3ec \uc7ac\ud504\ub85c\uadf8\ub798\ubc0d \uce58\ub8cc, \uc904\uae30\uc138\ud3ec \ubc0f \uc7ac\uc0dd \uce58\ub8cc, \uba74\uc5ed \uce58\ub8cc, \ub9c8\uc774\ud06c\ub85c\ubc14\uc774\uc634 \uc870\uc791 \ub4f1\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4. \ud2b9\ud788 \uc720\uc804\uc790 \uce58\ub8cc\ub294 \ubca1\ud130 \uacf5\ud559\uc744 \ud1b5\ud55c \uba74\uc5ed\uc6d0\uc131 \uc7a5\uc560 \uac10\uc18c\ub85c \uc778\ud574 \uc5f0\ud3c9\uade0 11.63%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uce58\ub8cc\ubc95\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<br \/>\n\uc804\ub2ec \ud50c\ub7ab\ud3fc\uc740 \uc0dd\uccb4 \ub0b4 \uce58\ub8cc\uc81c(In-vivo Therapeutics), \uc0dd\uccb4 \uc678\/\uc138\ud3ec \uae30\ubc18 \ud50c\ub7ab\ud3fc(Ex-vivo\/Cell-based Platforms), \ub514\uc9c0\ud138 \uc7a5\uc218 \uac1c\uc785(Digital Longevity Interventions)\uc73c\ub85c \ub098\ub269\ub2c8\ub2e4. \ub514\uc9c0\ud138 \uc7a5\uc218 \ud50c\ub7ab\ud3fc\uc740 \ud6c4\uc131\uc720\uc804\ud559\uc801 \uc5f0\ub839 \uac10\uc18c\uc640 \uc785\uc6d0 \ube44\uc6a9 \uc808\uac10 \uac04\uc758 \uc0c1\uad00\uad00\uacc4\ub85c \uc778\ud574 \ubcf4\ud5d8\uc0ac\ub4e4\uc758 \uad00\uc2ec\uc744 \ub04c\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n\uc801\uc6a9 \ubd84\uc57c\ub294 \uc2ec\ud608\uad00 \uc9c8\ud658, \uc2e0\uacbd \ud1f4\ud589\uc131 \uc9c8\ud658, \ub300\uc0ac \uc9c8\ud658(\ub2f9\ub1e8\ubcd1, \ube44\ub9cc), \uc885\uc591\ud559\uc801 \uc801\uc751\uc99d, \uadfc\uace8\uaca9\uacc4 \ubc0f \ud5c8\uc57d, \ud53c\ubd80\uacfc \ubc0f \ubbf8\uc6a9, \uc548\uacfc \ub4f1\uc73c\ub85c \ub2e4\uc591\ud569\ub2c8\ub2e4.<br \/>\n\ucd5c\uc885 \uc0ac\uc6a9\uc790\ub294 \uc81c\uc57d \ubc0f \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5, \ud559\uc220 \ubc0f \uc5f0\uad6c \uae30\uad00, CRO(\uc784\uc0c1\uc2dc\ud5d8\uc218\ud0c1\uae30\uad00) \ubc0f CDMO(\uc704\ud0c1\uac1c\ubc1c\uc0dd\uc0b0\uae30\uad00), \uc6f0\ub2c8\uc2a4 \ud074\ub9ac\ub2c9 \ubc0f \uc7a5\uc218 \uc2a4\ud30c \ub4f1\uc73c\ub85c \uad6c\uc131\ub429\ub2c8\ub2e4.<br \/>\n\uc9c0\uc5ed\ubcc4\ub85c\ub294 \ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8\ub85c \uad6c\ubd84\ub418\uba70, \uc77c\ubcf8\uacfc \uc911\uad6d\uc758 \uc815\ucc45 \uc9c0\uc6d0\uc5d0 \ud798\uc785\uc5b4 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uc5f0\ud3c9\uade0 10.35%\ub85c \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd\uc740 50\uac1c \uc774\uc0c1\uc758 \uc784\uc0c1 \ub2e8\uacc4 \uae30\uc5c5\uc774 \uc874\uc7ac\ud558\uba70, \ub2e8\uc77c \uae30\uc5c5\uc774 5% \uc774\uc0c1\uc758 \ub9e4\ucd9c \uc810\uc720\uc728\uc744 \ucc28\uc9c0\ud558\uc9c0 \uc54a\ub294 \ub9e4\uc6b0 \ubd84\uc0b0\ub41c \ud615\ud0dc\ub97c \ub760\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc8fc\uc694 \uae30\uc5c5\uc73c\ub85c\ub294 AbbVie Inc., AgeX Therapeutics, Altos Labs, BioAge Labs, Bristol-Myers Squibb, Calico Life Sciences, Eli Lilly and Company, GlaxoSmithKline plc, Insilico Medicine, Pfizer Inc., Unity Biotechnology \ub4f1\uc774 \uc5b8\uae09\ub429\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc7a5\uc218 \uc2dc\uc7a5\uc758 \ud604\uc7ac\uc640 \ubbf8\ub798\ub97c \uc885\ud569\uc801\uc73c\ub85c \uc870\ub9dd\ud558\uba70, \uc2dc\uc7a5 \ucc38\uc5ec\uc790\ub4e4\uc774 \uc804\ub7b5\uc801 \uc758\uc0ac\uacb0\uc815\uc744 \ub0b4\ub9ac\ub294 \ub370 \ud544\uc694\ud55c \uc2ec\uce35\uc801\uc778 \ud1b5\ucc30\ub825\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29125","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/29125"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=29125"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/29125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=29125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=29125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=29125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}